EN DE
STOCK COMPARISON

AstraZeneca vs Johnson & Johnson: Fair Value & Quality

Both stocks run through our valuation models. Here is how AstraZeneca (AZN) and Johnson & Johnson (JNJ) compare, as of Sep 4, 2026.

As of Sep 4, 2026, Fair Value Calculator sees AstraZeneca as the less overvalued of the two: AstraZeneca trades at $165 versus a fair value of $127 (-23%), while Johnson & Johnson trades at $278 versus $169 (-39%).
AstraZeneca
AZN · USD · Health Care
-23%
upside to fair value
overvalued
Price$165
Fair Value$127
Quality69/100
Johnson & Johnson
JNJ · USD · Health Care
-39%
upside to fair value
overvalued
Price$278
Fair Value$169
Quality82/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

AstraZenecaJohnson & Johnson
Valuation
24.8×P/E (TTM)29.4×
4.49×P/S (TTM)6.34×
5.58×P/B7.49×
14.5×EV/EBITDA18.4×
1.36×PEG4.95×
−22.7%Fair value upside−39.3%
1.9%Dividend yield1.9%
$3.20Dividend per share$5.20
Profitability
28%Operating margin27%
1.21×EBIT margin trend (5Y)1.14×
23%Return on equity26%
8%Return on assets8%
Growth
13%Revenue growth (YoY)10%
9.8%Avg. growth/yr (3Y)5.6%
17.2%Avg. growth/yr (5Y)2.7%
+46.8%Value creation/yr+15.2%
Balance & size
8.1×Interest coverage (EBIT/interest)26.4×
0.51×Debt / equity0.48×
$271BMarket cap$611B
healthyGrowth qualityhealthy

AstraZeneca leads: 11 to 2 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

AstraZenecaof which business quality 65 · market factors 49 Johnson & Johnsonof which business quality 76 · market factors 88
ProfitabilityMargins and returns on capital today
63
74
Quality GrowthAre margins and returns improving?
65
73
CashflowEarnings quality: real cash, not paper profit
63
70
Fin. StrengthBalance sheet, leverage, solvency risk
60
72
InvestmentDisciplined investing over empire-building
60
87
Low VolatilityCalm price path (market factor)
85
96
MomentumPrice trend over the last 3–12 months (market factor)
31
75
52W MomentumDistance to the 52-week high (market factor)
39
100
Net IssuanceBuybacks instead of dilution
82
90

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyAstraZenecaPrice $165Johnson & JohnsonPrice $278
DCF Models-30%below the price$116-39%below the price$171
Earnings-Based-63%below the price$60.23-74%below the price$73.34
Dividend Discountn/a-66%below the price$93.41
Multiples-24%below the price$125-42%below the price$163
Asset-Based-87%below the price$21.03-92%below the price$22.70
Growth DCF-39%below the price$100-54%below the price$129
Economic Profit-54%below the price$75.73-64%below the price$102
Growth Earnings-22%below the price$129-26%below the price$207
Minimum-87%below the price$21.03-92%below the price$22.70
Maximum-22%below the price$129-26%below the price$207
Median-39%below the price$100-59%below the price$115
Geometric mean-52%below the price$78.30-63%below the price$102

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

AstraZeneca: 24 of 24 models see the stock below the current price.

Johnson & Johnson: 26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

AstraZeneca
Bear $72.51Fair Value $127Bull $173
$165 = current price (white tick)
Johnson & Johnson
Bear $106Fair Value $169Bull $255
$278 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

AstraZeneca · Health Care

Quality score69 · Top 25%
Fair value upside-23% · above median

Johnson & Johnson · Health Care

Quality score82 · Top 25%
Fair value upside-39% · below median

Bottom line

As of Sep 4, 2026, Fair Value Calculator sees AstraZeneca as the less overvalued of the two: AstraZeneca trades at $165 versus a fair value of $127 (-23%), while Johnson & Johnson trades at $278 versus $169 (-39%).

Johnson & Johnson has the higher quality score (82/100).

See the full analysis →
AstraZeneca · Johnson & Johnson

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to AstraZeneca

AstraZeneca vs UnitedHealth GroupEli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth Group

Related to Johnson & Johnson

Merck & Company vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAmgen vs UnitedHealth GroupAbbott Laboratories vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.